Precision BioSciences, Inc.
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
173 articles with Precision BioSciences, Inc.
-
Precision BioSciences Appoints Juli Blanche as Chief People Officer
5/23/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences.
-
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
5/18/2022
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection.
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
5/16/2022
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting.
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
5/12/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.
-
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
5/9/2022
Precision BioSciences, Inc. today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
5/2/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting.
-
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
5/2/2022
Precision BioSciences, Inc today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
3/15/2022
Precision BioSciences, Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2021.
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
3/8/2022
Precision BioSciences, Inc. today announced that it will publish financial results for the fourth quarter and fiscal year 2021 and provide a business update on March 15, 2022.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
1/4/2022
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference.
-
Precision BioSciences Completes Spin-Out of Elo Life Systems
12/21/2021
Precision BioSciences, Inc. today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary and create an independent food and agriculture business.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
12/11/2021
Precision BioSciences, Inc., a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion 1 presented at the 63rd American Society of Hematology Annual Meeting.
-
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
12/6/2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting.
-
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
12/3/2021
Precision BioSciences, Inc. today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.
-
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
Precision BioSciences, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
11/9/2021
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
-
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
11/8/2021
Precision BioSciences, Inc. today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company’s Board of Directors.